| 货号 | HV811016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Humanized |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | FGF-inducible 14, TNFRSF12A, FN14, CD266, TweakR, Fibroblast growth factor-inducible immediate-early response protein 14, Tweak-receptor, Tumor necrosis factor receptor superfamily member 12A |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q9NP84 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | PDL192, 1062149-33-0 |
| 背景 | Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo . • TWEAK/Fn14 signaling in tumors., PMID:28639899 • The TWEAK/Fn14/CD163 axis-implications for metabolic disease., PMID:34542797 • TWEAK/Fn14 axis in respiratory diseases., PMID:32526219 • TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer., PMID:38965263 • Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges., PMID:32053869 • Role of the TWEAK/Fn14 pathway in autoimmune diseases., PMID:26659091 • TWEAK/Fn14 signaling: a promising target in intervertebral disc degeneration., PMID:26907852 • Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration., PMID:32200423 • Role of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in rheumatic diseases., PMID:23106895 • Tumor Necrosis Factor Receptor Mediates Fibroblast Growth Factor-Inducible 14 Signaling., PMID:28934756 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Enavatuzumab.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
